Godavari Biorefineries stock jumps 5% on Chinese patent for cancer drug

At 01:35 PM, shares of Godavari Biorefineries were trading at ₹327.43, up by 5 per cent on the National Stock Exchange

stock prices, Nifty Smallcap, stock market, initial public offering, IPO
The patent covers a novel class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells in vitro studies.
SI Reporter New Delhi
2 min read Last Updated : Jul 22 2025 | 2:17 PM IST
Godavari Biorefineries share price today: Shares of Godavari Biorefineries surged 5 per cent on Tuesday, July 22, 2025, recording an intraday high of ₹327.43 per share.
 
At 01:35 PM, shares of Godavari Biorefineries were trading at the day's highest level on the National Stock Exchange. In comparison, NSE Nifty was trading largely flat at 25,082.45, down by 8 points. The total market capitalisation of the company stood at ₹1,675.66 crore. So far this calendar year, the shares of the company have remained flat, albeit in the red territory, down by just over 1 per cent.

Why were Godavari Biorefineries' shares buzzing in trade?

The buying on the counter came after the company announced in a latest exchange filing that its clinical-stage biotech division, Sathgen Therapeutics, was granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anticancer molecule.
 
The patent covers a novel class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer, as per the exchange filing.
 
"Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,” said Dr. Sangeeta Srivastava, executive director, Godavari Biorefineries. “This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide," she added. 
 
Godavari Biorefineries already has an established presence on the global front. Its biotech division, Sathgen Therapeutics, is actively involved in the development of novel cancer and antiviral therapies. 
It is also worth mentioning that just earlier this month, the company was granted a patent in Europe for its novel anticancer molecule.

About Godavari Biorefineries

Godavari Biorefineries was originally incorporated as 'Godavari Investment and Finance Corporation Ltd.' in Mumbai on January 12, 1956. The name of the company was changed on November 10, 2006, as 'Godavari Biorefineries'. The company is involved in the manufacturing of ethanol-based chemicals in India and has one of the largest integrated bio-refineries in the country in terms of installed capacity.
     
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Stock MarketBuzzing stocksMarketsBio-ethanolNiftyPatents

First Published: Jul 22 2025 | 2:16 PM IST

Next Story